{
    "organizations": [],
    "uuid": "3876d50eef64600c5ad233d7092ff48774cd1a50",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alnylam-receives-positive-opinion/brief-alnylam-receives-positive-opinion-for-orphan-drug-designation-in-eu-for-aln-ttrsc02-for-treatment-of-transthyretin-mediated-amyloidosis-idUSASO0003OG",
    "ord_in_thread": 0,
    "title": "BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 25 AM / Updated 8 minutes ago BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis Reuters Staff 1 Min Read \nApril 23 (Reuters) - Alnylam Pharmaceuticals Inc: \n* ALNYLAM RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ALN-TTRSC02, A SUBCUTANEOUSLY DELIVERED INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Source text for Eikon: Further company coverage:",
    "published": "2018-04-23T14:25:00.000+03:00",
    "crawled": "2018-04-23T14:36:17.028+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "receives",
        "positive",
        "opinion",
        "orphan",
        "drug",
        "designation",
        "eu",
        "treatment",
        "amyloidosis",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "alnylam",
        "pharmaceutical",
        "inc",
        "alnylam",
        "receives",
        "positive",
        "opinion",
        "orphan",
        "drug",
        "designation",
        "european",
        "union",
        "subcutaneously",
        "delivered",
        "investigational",
        "rnai",
        "therapeutic",
        "treatment",
        "amyloidosis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}